Congenital structural myopathy
MONDO:0002921A group of rare genetic muscle disorders characterized by hypotonia, muscle weakness, and delayed development of motor skills.
Also known as: centronuclear myopathy
65 clinical trials for this condition and its sub-types, 5 tagged with Congenital structural myopathy itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Part of
Sub-types of Congenital structural myopathy
-
Inborn mitochondrial myopathy 18 trials · 45 incl. sub-types
24 sub-types
- Mitochondrial encephalomyopathy 3 trials · 15 incl. sub-types Sub-types →
- Progressive external ophthalmoplegia 4 trials · 8 incl. sub-types Sub-types →
- Barth syndrome 5 trials
- Mitochondrial neurogastrointestinal encephalomyopathy 4 trials Sub-types →
- Mitochondrial trifunctional protein deficiency 3 trials Sub-types →
- Myopathy, lactic acidosis, and sideroblastic anemia 3 trials Sub-types →
- Adenosine monophosphate deaminase deficiency 1 trial
- Sensory ataxic neuropathy, dysarthria, and ophthalmoparesis 1 trial Sub-types →
- COX deficiency, benign infantile mitochondrial myopathy 0 trials
- X-linked recessive mitochondrial myopathy 0 trials
- Adult-onset chronic progressive external ophthalmoplegia with mitochondrial myopathy 0 trials Sub-types →
- Autosomal dominant mitochondrial myopathy with exercise intolerance 0 trials
- Congenital cataract-progressive muscular hypotonia-hearing loss-developmental delay syndrome 0 trials
- Fatal infantile encephalocardiomyopathy 0 trials Sub-types →
- Lethal infantile mitochondrial myopathy 0 trials
- Maternally-inherited progressive external ophthalmoplegia 0 trials
- Mitochondrial complex I deficiency, nuclear type 1 0 trials
- Mitochondrial complex II deficiency, nuclear type 0 trials Sub-types →
- Mitochondrial myopathy with a defect in mitochondrial-protein transport 0 trials
- Mitochondrial myopathy with diabetes 0 trials
- Mitochondrial myopathy with reversible cytochrome C oxidase deficiency 0 trials
- Mitochondrial myopathy, episodic, with optic atrophy and reversible leukoencephalopathy 0 trials
- Mitochondrial myopathy-cerebellar ataxia-pigmentary retinopathy syndrome 0 trials
- Mitochondrial myopathy-lactic acidosis-deafness syndrome 0 trials
-
Nemaline myopathy 13 trials
8 sub-types
- Childhood-onset nemaline myopathy 1 trial · 2 incl. sub-types Sub-types →
- Nemaline myopathy 5 2 trials
- Severe congenital nemaline myopathy 0 trials · 1 incl. sub-types Sub-types →
- MYPN-related myopathy 0 trials
- Adult-onset nemaline myopathy 0 trials
- Nemaline myopathy 5B, autosomal recessive, childhood-onset 0 trials
- Nemaline myopathy 5C, autosomal dominant 0 trials
- Typical nemaline myopathy 0 trials Sub-types →
-
Myofibrillar myopathy 1 trial · 3 incl. sub-types
13 sub-types
- Central core myopathy 2 trials
- Fatal infantile hypertonic myofibrillar myopathy 0 trials
- Myofibrillar myopathy 1 0 trials
- Myofibrillar myopathy 10 0 trials
- Myofibrillar myopathy 11 0 trials
- Myofibrillar myopathy 3 0 trials
- Myofibrillar myopathy 4 0 trials
- Myofibrillar myopathy 5 0 trials
- Myofibrillar myopathy 6 0 trials
- Myofibrillar myopathy 7 0 trials Sub-types →
- Myofibrillar myopathy 8 0 trials
- Myopathy, myofibrillar, 12, infantile-onset, with cardiomyopathy 0 trials
- Myopathy, myofibrillar, 13, with rimmed vacuoles 0 trials
-
1 sub-type
Most studied deeper sub-types
-
New drug aims to tame hard-to-control seizures in rare mitochondrial disorders
Disease control Stopped earlyThis study tested a drug called vatiquinone in 68 people with mitochondrial disease and epilepsy that doesn't respond to standard treatments. Participants were randomly assigned to receive either vatiquinone or a placebo for 24 weeks to see if the drug could reduce the number of …
Phase 2/3 • Sponsor: PTC Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New drug OMS721 tested for rare kidney conditions
Disease control Stopped earlyThis study tested a drug called OMS721 in 31 people with certain kidney diseases, including IgA nephropathy and lupus nephritis. The main goal was to check if the drug is safe and if it reduces protein in the urine, a sign of kidney damage. The study was stopped early, so results…
Phase 2 • Sponsor: Omeros Corporation • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC